Background
==========

Peanuts are one of the most common foods causing allergic reactions in children. IgE-ab sensitization to peanut has been reported in 7--11% of children in Western countries and the prevalence of peanut allergy (PA) in children varies between 0.75% and 3%. Given the PA impact on quality-of-life (QoL), accurate diagnosis is crucial because many sensitized individuals are actually tolerant to peanut. Peanut sensitization established by IgE antibodies (IgE-ab) in blood or skin prick test (SPT) often needs to be confirmed by the "gold standard" Double-blind placebo-controlled food challenge (DBPCFC), a risky and expensive procedure. In clinical practice an open oral food challenge (OC) is performed instead of a DBPCFC. PA can be effectively diagnosed using molecular allergology (MA), identifying subjects at risk for PA reactions (IgE-ab to Ara h 1-2-3). No cost-effectiveness (CE) analyses are available on MA for allergy.

Methods
=======

Three 5-year Markov models simulate the flow of 200 children PA suspected presenting to the general practitioner. The models compare different diagnostic approaches (DBPCFC, OC, SPT and MA), computing the cost-per-QALY (Quality Adjusted Life Year) gained based on data from the literature. Calculations were performed for Sweden and BaseCase® was used to present results. Care giver indirect costs are included in a sensitivity analysis.

Results
=======

In Sweden, cost-per-QALY is 3.66 for SPT, 3.22 for DBPCFC, 2.23 for OC and 4.34 for MA. The cost for different diagnostic approaches is:

\- SPT: 44851 SEK

\- DBPCFC: 24278 SEK

\- OC: 33031SEK

\- MA: 11267 SEK

Conclusion
==========

In Sweden, MA increases QoL, and it is associated with reduced costs per patient with respect to the other strategies. The hypothesized usage of MA could be a valid alternative and a useful diagnostic tool replacing the "gold standard" DBPCFC in selected cases, DBPCFC still being useful in subjects with conflicting immunological/clinical results.
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